
Release date: 2026-03-05 17:16:17 Article From: Lucius Laos Recommended: 2
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 tyrosine kinase inhibitor developed by Pfizer Inc., USA.
When taking Lorlatinib, seek medical attention immediately if you experience any of the following side effects:
(1) Loss of control of behavior, aggression, agitation, anxiety, black, tarry stools, bleeding gums, blood in the urine or stools, blurred vision or other vision changes, body aches or pain, burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings;
(2) Changes in behavior, chills, cough, deficits in intelligence, short-term memory, learning ability, and concentration, difficulty or trouble breathing, discouragement, dizziness, dry mouth, feeling of fullness in the ears, false or unusual sense of well-being, feelings of sadness or emptiness, fever;
(3) Flushing, dryness of the skin, fruity breath odor, headache, hoarseness or loss of voice, increased appetite, increased thirst, increased urine output, irritability, loss of appetite, loss of interest or pleasure, lower back or side pain, nausea, nervousness;
(4) Painful or difficult urination, pale skin, pinpoint red spots on the skin, ringing in the ears, runny or stuffy nose, seeing, hearing, or feeling things that are not there, skin rash, slow or fast heartbeat, sneezing, sore throat, stomach pain, sweating, swelling;
(5) Talkativeness, mood, and behavior that are overly excited, thoughts of suicide or self-harm, tightness in the chest, trouble concentrating, trouble sleeping, trouble breathing, unexplained weight loss, unsteadiness or clumsiness, unusual bleeding or bruising, unusual tiredness or weakness, vomiting, weakness in the arms, hands, legs, or feet.
When taking Lorlatinib, consult your healthcare professional if any of the following side effects persist, are bothersome, or if you have any questions about them:
Abnormal dreams, back pain, constipation, difficulty with moving, difficulty speaking, drowsiness, joint pain, muscle aches, cramps, pain, or stiffness, pain in the arms or legs, talking in your sleep, swelling of the joints.
Lucius Pharmaceuticals Lorlatinib Side Effects Reference for Healthcare Professionals
(1) Musculoskeletal
Arthralgia, myalgia/musculoskeletal pain, back pain, pain in extremity.
(2) Ocular
Visual disturbance (e.g., diplopia, photophobia, flashes of light, blurred vision, reduced visual acuity, visual impairment, vitreous floaters).
(3) Metabolic
Hypercholesterolemia, hypertriglyceridemia, edema (peripheral edema, eyelid edema, face edema, generalized edema, localized edema, periorbital edema, peripheral swelling, swelling), hyperglycemia, hypoalbuminemia, weight increased, lipase increased, alkaline phosphatase increased, amylase increased, hypophosphatemia, hyperkalemia, hypomagnesemia, Grade 3 or 4 total cholesterol increased, Grade 3 or 4 triglycerides increased.
(4) Psychiatric
Cognitive effects (e.g., amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment, attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, dyslexia), mood effects, sleep effects (e.g., abnormal dreams, insomnia, nightmare, sleep disorder, sleep talking, somnambulism).
(5) Hepatic
Grade 4 ALT/AST increased (when used with strong CYP3A inducers), Grade 3 ALT/AST increased (when used with strong CYP3A inducers).
(6) Respiratory
Dyspnea, cough, upper respiratory tract infection (e.g., fungal upper respiratory infection, viral upper respiratory infection).
(7) Hematologic
Anemia, thrombocytopenia, lymphopenia.
(8) Nervous System
Peripheral neuropathy (e.g., burning sensation, carpal tunnel syndrome, formication, gait disturbance, hypoesthesia, muscular weakness, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral sensory neuropathy, sensory disturbance), speech disorder (e.g., aphasia, dysarthria, slow speech).
(9) Skin
Rash (e.g., acneiform dermatitis, maculopapular rash, pruritic rash, rash).
(10) Other
Asthenia/fatigue, pyrexia.
Common Adverse Reactions (Incidence 1%-10%)
(1) Psychiatric
Hallucination, mental status changes.
(2) Hepatic
Grade 2 ALT/AST increased (when used with strong CYP3A inducers).
(3) Respiratory
Interstitial lung disease (ILD), pneumonitis.
(4) Nervous System
Seizure.
(5) Cardiovascular
Atrioventricular block, hypertension.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1522025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3922024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1442025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1652025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1482025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1582025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1542025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: